Monthly Archives: March 2019

Spravato Esketamine: What We Know So Far

FDA approved a new nasal spray medication for treatment-resistant depression called Spravato, trade name for Esketamine on March 5, 2019.  We’ve had many inquiries about the medication at our practice and I thought it would be beneficial to all of you to share the information I have regarding this new medication. Spravato is a new antidepressant medication manufactured by Johnson & Johnson’s pharmaceutical company, Janssen, for management of Treatment Resistant Depression. According to the FDA, “Patients with major depressive disorder …
Read More »

Posted in Blog, Ketamine Treatment | Tagged , , | Comments Off on Spravato Esketamine: What We Know So Far